Anzeige
Mehr »
Freitag, 18.07.2025 - Börsentäglich über 12.000 News
Klinisch validiert. Vertriebsbereit. Und kurz vor der FDA-Zulassung.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40KLP | ISIN: US49876K1034 | Ticker-Symbol:
NASDAQ
17.07.25 | 22:00
1,360 US-Dollar
0,00 % 0,000
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
KLOTHO NEUROSCIENCES INC Chart 1 Jahr
5-Tage-Chart
KLOTHO NEUROSCIENCES INC 5-Tage-Chart

Aktuelle News zur KLOTHO NEUROSCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
KLOTHO NEUROSCIENCES Aktie jetzt für 0€ handeln
MiKlotho Clears Nasdaq Hurdle-KLTO Stock Remains On The Big Board1
MiKlotho Neurosciences regains NASDAQ compliance1
MiKlotho Neurosciences regains full compliance with Nasdaq listing standards2
MiKlotho Neurosciences, Inc. Regains Full Compliance with NASDAQ Minimum Closing Bid Price and Stockholder Equity Rules192Klotho Neurosciences Maintains Listing on the NASDAQ NEW YORK, July 16, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. ("Klotho" or the "Company") (NASDAQ: KLTO), a gene and cell therapy...
► Artikel lesen
10.07.Klotho Neurosciences, Inc. - 8-K, Current Report1
10.07.Klotho Neurosciences stock soars after FDA grants orphan drug status for ALS-
10.07.Klotho Neurosciences: Aktie schießt nach FDA-Sonderstatus für ALS-Therapie in die Höhe3
10.07.Klotho Neurosciences, Inc. Granted FDA Orphan Drug Designation for KLTO-202 for Treatment of Amyotrophic Lateral Sclerosis ("ALS" or "Lou Gehrig's Disease")77NEW YORK, July 10, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (Nasdaq: KLTO), a gene and cell therapy company focused on the treatment of neurodegenerative...
► Artikel lesen
30.06.Klotho Neurosciences, Inc. - 8-K, Current Report3
30.06.Klotho Neurosciences, Inc.: Klotho Neurosciences Moves Forward with Manufacturing Gene Therapy for the Treatment of ALS266NEW YORK, June 30, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO) today announced that it is moving forward with manufacturing and process development work in preparation...
► Artikel lesen
24.06.Klotho Neurosciences, Inc. and the Okinawa Research Center for Longevity Science, Leading Experts on the Okinawa "Blue Zone", Announce a Plan to Study Tissue Levels of the Human Klotho Gene and Protein in the World's Longest-Lived Population266NEW YORK, June 24, 2025 /PRNewswire/ -- Klotho Neuroscience, Inc. (NASDAQ: KLTO), a US-based biogenetics company developing cell and gene- based treatments to address neurological conditions...
► Artikel lesen
18.06.Klotho Neurosciences terminates share exchange agreement with SkyBell4
18.06.Klotho Neurosciences, Inc.: Klotho Neurosciences Announces Mutual Termination Of Share Exchange Agreement With Skybell Technologies, To Continue Its Focus On Therapeutics And Longevity Programs111Key highlights of the announcement include: Elimination of Future Dilution: The Company will no longer be required to issue new common stock to SkyBell, which...
► Artikel lesen
16.06.Klotho Neurosciences raises $11 million, eliminates all debt1
16.06.Klotho Neurosciences, Inc.: Klotho Neurosciences Raises Over $11 Million, Retires All Debt, And Exceeds Nasdaq Stockholders' Equity Requirement142Highlights: Over $11 Million Raised: Proceeds were generated through the exercise of existing warrants. Chardan Capital Markets was the exclusive financial advisor...
► Artikel lesen
10.06.Klotho Neurosciences, Inc. - 8-K, Current Report2
10.06.Klotho Neurosciences: What's Behind The Nine-Fold Rise In KLTO Stock?13
09.06.Klotho Neurosciences Stock Skyrockets 621% On Preclinical Longevity Findings21
02.06.Klotho Neurosciences, Inc. - 8-K, Current Report5
21.04.Klotho Neurosciences, Inc. - 8-K, Current Report2
Weiter >>
31 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1